- Home
- NGNE vs HRZN Comparison
NGNE vs HRZN Comparison
Compare NGNE & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- HRZN
- Stock Information
- Founded
- NGNE 2003
- HRZN 2008
- Country
- NGNE United States
- HRZN United States
- Employees
- NGNE N/A
- HRZN N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- HRZN Finance/Investors Services
- Sector
- NGNE Health Care
- HRZN Finance
- Exchange
- NGNE Nasdaq
- HRZN Nasdaq
- Market Cap
- NGNE 325.3M
- HRZN 295.3M
- IPO Year
- NGNE N/A
- HRZN 2010
- Fundamental
- Price
- NGNE $18.48
- HRZN $6.90
- Analyst Decision
- NGNE Strong Buy
- HRZN Hold
- Analyst Count
- NGNE 7
- HRZN 4
- Target Price
- NGNE $41.86
- HRZN $7.81
- AVG Volume (30 Days)
- NGNE 110.1K
- HRZN 684.1K
- Earning Date
- NGNE 08-11-2025
- HRZN 08-07-2025
- Dividend Yield
- NGNE N/A
- HRZN 19.13%
- EPS Growth
- NGNE N/A
- HRZN N/A
- EPS
- NGNE N/A
- HRZN N/A
- Revenue
- NGNE N/A
- HRZN $97,144,000.00
- Revenue This Year
- NGNE N/A
- HRZN $0.51
- Revenue Next Year
- NGNE N/A
- HRZN $9.90
- P/E Ratio
- NGNE N/A
- HRZN N/A
- Revenue Growth
- NGNE N/A
- HRZN N/A
- 52 Week Low
- NGNE $6.88
- HRZN $6.77
- 52 Week High
- NGNE $74.49
- HRZN $11.15
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- HRZN 30.61
- Support Level
- NGNE $19.59
- HRZN $6.86
- Resistance Level
- NGNE $20.46
- HRZN $6.96
- Average True Range (ATR)
- NGNE 1.23
- HRZN 0.09
- MACD
- NGNE -0.20
- HRZN -0.00
- Stochastic Oscillator
- NGNE 13.37
- HRZN 15.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.